Home LiteratureArticle Details
PMID: 17519900 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Mechanisms of adverse effects of anti-VEGF therapy for cancer.

British journal of cancer ·Vol. 96 ·No. 12 ·2007-06-18 ·Pages 1788-95

Kamba T, McDonald DM

Abstract

Advances in understanding the role of vascular endothelial growth factor (VEGF) in normal physiology are giving insight into the basis of adverse effects attributed to the use of VEGF inhibitors in clinical oncology. These effects are typically downstream consequences of suppression of cellular signalling pathways important in the regulation and maintenance of the microvasculature. Downregulation of these pathways in normal organs can lead to vascular disturbances and even regression of blood vessels, which could be intensified by concurrent pathological conditions. These changes are generally manageable and pose less risk than the tumours being treated, but they highlight the properties shared by tumour vessels and the vasculature of normal organs.

MeSH Terms
Angiogenesis Inhibitors/adverse effects Antibodies, Monoclonal/adverse effects Antibodies, Monoclonal, Humanized Antineoplastic Agents/adverse effects Benzenesulfonates/adverse effects Bevacizumab Hemorrhage/chemically induced Humans Indoles/adverse effects Neoplasms/drug therapy,pathology Niacinamide/analogs & derivatives Phenylurea Compounds Pyridines/adverse effects Pyrroles/adverse effects Signal Transduction/drug effects Sorafenib Sunitinib Thrombosis/chemically induced Vascular Endothelial Growth Factor A/antagonists & inhibitors,physiology Wound Healing/drug effects
Chemicals
Angiogenesis Inhibitors Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Agents Benzenesulfonates Indoles Phenylurea Compounds Pyridines Pyrroles Vascular Endothelial Growth Factor A Niacinamide Bevacizumab Sorafenib Sunitinib
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Kamba T
Department of Urology, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
McDonald D M
References (40)
40 references, click to expand
  1. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    N Engl J Med. 2004 Jun 3;350(23):2335-42 PMID: 15175435
  2. Bevacizumab, bleeding, thrombosis, and warfarin.
    J Clin Oncol. 2003 Sep 15;21(18):3542; author reply 3543 PMID: 12972536
  3. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
    J Surg Oncol. 2005 Sep 1;91(3):173-80 PMID: 16118771
  4. Polycythemia vera: myths, mechanisms, and management.
    Blood. 2002 Dec 15;100(13):4272-90 PMID: 12393615
  5. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.
    Arch Neurol. 2006 Oct;63(10):1475-8 PMID: 17030665
  6. Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules.
    Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H107-18 PMID: 16126815
  7. Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels.
    Circ Res. 2004 Apr 16;94(7):984-92 PMID: 15001532
  8. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.
    Am J Pathol. 2004 Jul;165(1):35-52 PMID: 15215160
  9. Sorafenib in advanced clear-cell renal-cell carcinoma.
    N Engl J Med. 2007 Jan 11;356(2):125-34 PMID: 17215530
  10. Tumor angiogenesis: therapeutic implications.
    N Engl J Med. 1971 Nov 18;285(21):1182-6 PMID: 4938153
  11. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
    J Clin Oncol. 2004 Jun 1;22(11):2184-91 PMID: 15169807
  12. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis.
    Nat Med. 2006 Jul;12(7):793-800 PMID: 16799557
  13. Sorafenib for the treatment of advanced renal cell carcinoma.
    Clin Cancer Res. 2006 Dec 15;12(24):7271-8 PMID: 17189398
  14. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells.
    Am J Physiol. 1998 Mar;274(3 Pt 2):H1054-8 PMID: 9530221
  15. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings.
    Semin Oncol. 2006 Oct;33(5 Suppl 10):S15-8 PMID: 17145520
  16. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology.
    Kidney Int. 2004 Jun;65(6):2003-17 PMID: 15149314
  17. Sunitinib in patients with metastatic renal cell carcinoma.
    JAMA. 2006 Jun 7;295(21):2516-24 PMID: 16757724
  18. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006.
    J Clin Oncol. 2006 Oct 1;24(28):e48 PMID: 17008686
  19. Chemotherapy induced reversible posterior leukoencephalopathy syndrome.
    Lung Cancer. 2007 Jun;56(3):459-63 PMID: 17316891
  20. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium.
    Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2793-800 PMID: 9409257
  21. Therapeutic options to target angiogenesis in human malignancies.
    Expert Opin Emerg Drugs. 2006 Nov;11(4):635-50 PMID: 17064223
  22. Sunitinib: from rational design to clinical efficacy.
    J Clin Oncol. 2007 Mar 1;25(7):884-96 PMID: 17327610
  23. The role of vascular endothelial growth factor in wound healing.
    Int J Low Extrem Wounds. 2003 Jun;2(2):107-20 PMID: 15866835
  24. Role of VEGF-A in vascularization of pancreatic islets.
    Curr Biol. 2003 Jun 17;13(12):1070-4 PMID: 12814555
  25. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling.
    Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H547-59 PMID: 16172161
  26. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
    Semin Oncol. 2006 Oct;33(5 Suppl 10):S26-34 PMID: 17145522
  27. Managing patients treated with bevacizumab combination therapy.
    Oncology. 2005;69 Suppl 3:25-33 PMID: 16301833
  28. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.
    Oncologist. 2006 Jul-Aug;11(7):753-64 PMID: 16880234
  29. Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
    J Clin Invest. 2006 Oct;116(10):2610-21 PMID: 17016557
  30. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor.
    Am J Physiol Cell Physiol. 2001 Jun;280(6):C1375-86 PMID: 11350732
  31. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
    J Clin Oncol. 2003 Jan 1;21(1):60-5 PMID: 12506171
  32. The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice.
    J Surg Res. 2005 Dec;129(2):251-9 PMID: 16140331
  33. VEGF at the neurovascular interface: therapeutic implications for motor neuron disease.
    Biochim Biophys Acta. 2006 Nov-Dec;1762(11-12):1109-21 PMID: 16784838
  34. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.
    J Clin Invest. 2003 Mar;111(5):707-16 PMID: 12618525
  35. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
    J Clin Oncol. 2005 Jun 1;23(16):3697-705 PMID: 15738537
  36. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis.
    Cancer Cell. 2002 Mar;1(2):193-202 PMID: 12086877
  37. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature.
    Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H560-76 PMID: 16172168
  38. Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation.
    Am J Physiol Gastrointest Liver Physiol. 2004 Oct;287(4):G757-63 PMID: 15191879
  39. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
    N Engl J Med. 2006 Dec 14;355(24):2542-50 PMID: 17167137
  40. Anti-angiogenic therapy: rationale, challenges and clinical studies.
    Angiogenesis. 2002;5(4):237-56 PMID: 12906317
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
DOI
10.1038/sj.bjc.6603813
Published
2007-06-18
Epub
2007-00-22
Pages
1788-95
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2359962
Subset
IM
Grants
NHLBI NIH HHS · P01 HL024136 · United States
NCI NIH HHS · R01 CA082923 · United States
NHLBI NIH HHS · HL59157 · United States
NHLBI NIH HHS · R01 HL059157 · United States
NCI NIH HHS · CA082923 · United States
NHLBI NIH HHS · HL24136 · United States
External Links
PubMed source DOI: 10.1038/sj.bjc.6603813 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2